Arbutus Biopharma Corp (ABUS)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Arbutus Biopharma Corp chart...

About the Company

arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.

CEO

Mark Murray

Exchange

NASDAQ

Website

http://www.arbutusbio.com/

$18M

Total Revenue

106

Employees

$445M

Market Capitalization

-5.89

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ABUS News

Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

15d ago, source:

Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders are probably feeling a little disappointed, since its ...

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

18d ago, source: Seeking Alpha

Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Fourth Quarter and Year End 2023 Financial Results and Corporate Update Conference Call. At this time, all participants ...

Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts

16d ago, source:

Today is shaping up negative for Arbutus Biopharma Corporation ( NASDAQ:ABUS) shareholders, with the analysts delivering a ...

Arbutus Biopharma files patent for lipid particles for stable delivery of therapeutic agents

6d ago, source: Pharmaceutical Technology

Discover Arbutus Biopharma's groundbreaking patent for stable lipid particles containing therapeutic agents. Learn about the innovative methods of making and delivering nucleic acid-lipid particles ...

Arbutus Biopharma to Participate in Prominent Investor Conferences

7d ago, source: MyChesCo on MSN

WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS), a biopharmaceutical company focused on discovering, developing ...

Buy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation Prospects

18d ago, source: Business Insider

Arbutus Biopharma (ABUS) Company Description: Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection.

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

18d ago, source: Stockhouse

WARMINSTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company ...

Q4 2023 Arbutus Biopharma Corp Earnings Call

18d ago, source: Yahoo Finance

Good day, and thank you for standing by. Welcome to the Arbutus fourth quarter corporate And financial update conference call. (Operator Instructions) Please be advised that today's conference is ...

Arbutus Biopharma Corp ABUS

25d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript

18d ago, source: Insider Monkey

Karen Sims: Sure, absolutely. So, as we said throughout this process, we certainly do intend to re-engage the FDA for this program. And really, the criteria for that is — are when we feel that ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...